Johnson & Johnson (NYSE:JNJ – Get Free Report)’s stock price traded up 0.7% during trading on Wednesday after Barclays raised their price target on the stock from $159.00 to $166.00. Barclays currently has an equal weight rating on the stock. Johnson & Johnson traded as high as $151.86 and last traded at $151.45. 1,567,021 shares changed hands during trading, a decline of 83% from the average session volume of 9,421,740 shares. The stock had previously closed at $150.38.
A number of other research firms also recently weighed in on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Citigroup dropped their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $170.44.
View Our Latest Research Report on Johnson & Johnson
Insider Buying and Selling
Institutional Trading of Johnson & Johnson
Large investors have recently made changes to their positions in the stock. Powers Advisory Group LLC boosted its stake in Johnson & Johnson by 0.6% in the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock worth $1,538,000 after purchasing an additional 61 shares during the period. Eagle Wealth Strategies LLC increased its holdings in shares of Johnson & Johnson by 2.8% during the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after acquiring an additional 63 shares in the last quarter. Knuff & Co LLC lifted its position in Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after acquiring an additional 64 shares during the period. Perkins Coie Trust Co boosted its position in Johnson & Johnson by 1.8% in the third quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock valued at $600,000 after buying an additional 65 shares during the last quarter. Finally, Vertex Planning Partners LLC lifted its holdings in shares of Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after buying an additional 65 shares during the period. 69.55% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Up 1.1 %
The company has a market cap of $367.82 billion, a PE ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s fifty day simple moving average is $147.73 and its two-hundred day simple moving average is $156.10.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the business posted $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.25%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Are Penny Stocks a Good Fit for Your Portfolio?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Canadian Penny Stocks: Can They Make You Rich?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.